



---

## **ASX Announcement and Media Release**

**Monday 30 January 2012**

**SciGen Ltd**

### **SCIGEN SECURES A STRONG PARTNER FOR THE COMMERCIALIZATION OF RECOMBINANT HUMAN INSULIN**

SciGen Limited (ASX:SIE) announced today that the Company has signed a Memorandum of Understanding with Actavis Group PTC ehf. (“**Actavis**”) for the sale of recombinant human insulin (“**Insulin**”) in 12 markets (“**Territory**”) of the Asia-Pacific, as well as the Middle East and Africa regions. Certain Middle East and Africa markets have been recently obtained by SciGen as a result of renegotiated terms of the license agreement with Ferring S.A.

The Parties have agreed that Actavis will pay to SciGen a consideration of up to EUR 1,400,000 including EUR 1,000,000 at signing of the final agreements. Both Parties expect that sales of the Insulin by Actavis into some of the markets of the Territory shall commence on the turn of 2012 and 2013. The profits from the sale of the Insulins in the Territory will be shared on an equal basis (50/50).

Formal documentation of these arrangements is expected to be concluded in the following weeks.

#### **About Actavis**

Actavis is part of the Actavis Group, one of the leading pharmaceutical concerns developing and manufacturing modern generic medicines. At present, the Actavis Group has a portfolio, which includes approximately 830 medicines present on the market and registered in more than 70 countries. Moreover, Actavis has a portfolio of 315 pharmaceutical products in its pipeline. The Actavis Group was established in 1956 and currently employs over 10,000 employees and conducts business activities in over 40 countries.

#### **About SciGen**

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology, oncology, neurology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in India and China and a contract manufacturer in Poland, Bioton S.A.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638